Antibody–drug conjugates (ADCs) combine the targeting capabilities of antibodies with the potent cytotoxicity of chemotherapy drugs, or “payloads.” By selectively delivering highly toxic drugs directly to tumor cells, ADCs aim to maximize efficacy while minimizing harm to healthy tissue. ADCs consist of three main components: a monoclonal antibody, a cytotoxic drug (payload), and a linker that connects the two. Each of these components can be engineered to improve ADC performance, including factors like specificity, stability, and controlled drug release.
Mechanism of Action and Benefits of ADCs in Cancer Treatment
The monoclonal antibody in an ADC is designed to target specific antigens highly expressed on tumor cells. Once bound to its target, the ADC is internalized by the cancer cell, and the payload is released inside the cell to exert its cytotoxic effects. This approach allows ADCs to selectively kill cancer cells while sparing most normal cells, offering a more targeted and potentially less toxic alternative to traditional chemotherapy.
ADCs have shown promise in treating several types of cancers. However, challenges such as drug resistance, tumor heterogeneity (variations within and between tumors), and treatment-related adverse effects (TRAEs) have limited their efficacy. Addressing these issues has led to the development of novel ADC formats, each designed to address specific challenges and enhance the therapeutic efficacy of ADCs.
Related: The Evolution of Antibody-Drug Conjugates (ADCs) in Cancer Therapy
Emerging ADC Formats and Their Unique Capabilities
Several new ADC formats have been developed to improve upon traditional ADCs, each offering distinct advantages to address issues like resistance and specificity:
Bispecific ADCs: These ADCs can bind two different antigens simultaneously, increasing the specificity of cancer targeting. This dual-binding ability helps address tumor heterogeneity, where different cells within a tumor or between tumors express varying antigens, making bispecific ADCs a powerful tool against diverse cancer cell populations.
Probody–Drug Conjugates (PDCs): PDCs, also known as conditionally active ADCs, are designed to remain inactive in healthy tissue and activate only in the tumor microenvironment. By reducing off-target effects, PDCs may lower the risk of adverse effects, enhancing both the safety and specificity of the therapy.
Immune-Stimulating ADCs (ISACs): Unlike traditional ADCs, ISACs are designed to stimulate the immune system in addition to delivering a cytotoxic payload. By recruiting immune cells to the tumor site, ISACs offer a dual mode of action that combines direct cancer cell killing with immunomodulation, potentially enhancing the overall antitumor response.
Protein-Degrader ADCs: These ADCs utilize a payload that induces the degradation of specific proteins within the cancer cell, rather than simply inhibiting them. This can target “undruggable” proteins—those that are difficult to target with conventional drugs—offering a new approach to kill cancer cells by disrupting essential protein functions.
Dual-Drug ADCs: By delivering two different cytotoxic agents in one ADC, dual-drug ADCs can address drug resistance and tumor heterogeneity more effectively. The combination of two drugs with different mechanisms of action can enhance therapeutic efficacy by targeting multiple pathways within cancer cells.
Related: Antibody-Drug Conjugates (ADCs) and Drug–Antibody Ratio (DAR)
Advances in ADC Components
The development of ADCs requires innovations across each component—antibody, linker, payload, and conjugation chemistry—to improve performance and safety:
Antibody Selection and Engineering: Selecting antibodies with high specificity for cancer antigens minimizes off-target effects. Bispecific antibodies, for instance, allow ADCs to bind multiple tumor markers, improving efficacy in heterogeneous tumors.
Linker Design: Linkers play a critical role in ensuring that the payload remains stable in the bloodstream and is released only within the tumor cell. Both cleavable linkers (activated by conditions within the tumor cell) and non-cleavable linkers (degraded within the cell) have been optimized to improve the control of payload release.
Payload Engineering: ADC payloads are typically highly cytotoxic, and recent advancements have expanded the types of payloads available, including drugs that induce protein degradation. Payload selection is critical to determining the ADC’s potency and mechanism of action, and dual-drug payloads offer an option for addressing multi-drug resistance.
Conjugation Chemistry: The method by which the payload is attached to the antibody affects the ADC’s stability and consistency. Site-specific conjugation, where the drug is attached at specific points on the antibody, improves stability and pharmacokinetics, leading to more predictable therapeutic outcomes.
Importance of Biomarker Identification and Patient Stratification
Reliable biomarkers help identify which patients are most likely to benefit from a specific ADC, enabling personalized cancer therapy. For example, identifying tumor antigens that are highly expressed in certain cancers helps tailor the antibody component of ADCs to those cancers, increasing the likelihood of success. This approach is especially important for emerging ADC formats, where multiple mechanisms of action or immunostimulatory components may interact with patient-specific factors.
Future Perspectives: Combining ADCs with Multimodal Cancer Treatments
The unique mechanisms of action of emerging ADCs suggest new opportunities for combination therapies that integrate ADCs with other cancer treatments, such as:
Chemotherapy and Radiotherapy: ADCs can be combined with traditional therapies to improve outcomes by targeting different aspects of cancer biology.
Immunotherapy: Immune-stimulating ADCs, when combined with immune checkpoint inhibitors, could amplify the immune response against cancer cells.
Targeted Therapies: Protein-degrader ADCs could target specific cancer-driving proteins that are not easily druggable with small molecules, opening new possibilities for combination treatments.
References:
Tsuchikama, K., Anami, Y., Ha, S. Y., & Yamazaki, C. M. (2024). Exploring the next generation of antibody–drug conjugates. Nature Reviews Clinical Oncology, 21(3), 203-223. https://www.nature.com/articles/s41571-023-00850-2
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
